ArticleACS medicinal chemistry letters2021

BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.

Robert J Cherney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.